Journal article

Augmented reduced-intensity regimen does not improve postallogeneic transplant outcomes in acute myeloid leukemia

Abstract:: PURPOSE: Reduced-intensity conditioning (RIC) regimens have extended the curative potential of allogeneic stem-cell transplantation to older adults with high-risk acute myeloid leukemia (AML) and myelodysplasia (MDS) but are associated with a high risk of disease relapse. Strategies to reduce recurrence are urgently required. Registry data have demonstrated improved outcomes using a sequential transplant regimen, fludarabine/amsacrine/cytarabine-busulphan (FLAMSA-Bu), but ...
Expand abstract
Collapse abstract

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Cite

Cite this record

APA Style

Craddock, C., Jackson, A., Loke, J., Siddique, S., Hodgkinson, A., Mason, J., Andrew, G., Nagra, S., Malladi, R., Peniket, A., Gilleece, M., Salim, R., Tholouli, E., Potter, V., Crawley, C., Wheatley, K., Protheroe, R., Vyas, P., Hunter, A., … Freeman, S. D. (2020). Augmented reduced-intensity regimen does not improve postallogeneic transplant outcomes in acute myeloid leukemia. Journal of Clinical Oncology, 39(7), 768–778.

MLA Style

Craddock, C., et al. “Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia.” Journal of Clinical Oncology, vol. 39, no. 7, American Society of Clinical Oncology, 2020, pp. 768–78.

Chicago Style

Craddock, C, A Jackson, J Loke, S Siddique, A Hodgkinson, J Mason, G Andrew, et al. 2020. “Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia.” Journal of Clinical Oncology 39 (7): 768–78.
Tweet
Print

Access Document

Files:: CraddocketalVoR2020.pdf

(Preview, Version of record, 516.5KB, Terms of use)

Publisher copy:: 10.1200/jco.20.02308

Authors

+ Craddock, C More by this author

Role:

Author

+ Jackson, A More by this author

Role:

Author

+ Loke, J More by this author

Role:

Author

+ Siddique, S More by this author

Role:

Author

+ Hodgkinson, A More by this author

Role:

Author

More authors...

Bibliographic Details

Publisher:: American Society of Clinical Oncology
Journal:: Journal of Clinical Oncology More from this journal
Volume:: 39
Issue:: 7
Pages:: 768-778
Publication date:: 2020-12-29
Acceptance date:: 2020-12-01
DOI:: 10.1200/jco.20.02308
EISSN:: 1527-7755
ISSN:: 0732-183X
Pmid:: 33373276

Item Description

Language:: English
Keywords:: FFR
Pubs id:: 1151733
Local pid:: pubs:1151733
Deposit date:: 2021-01-19

Terms of use

Copyright holder:: American Society of Clinical Oncology.
Copyright date:: 2020
Rights statement:: © 2020 by American Society of Clinical Oncology. Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by-nc-nd/4.0/

Licence:: CC Attribution-NonCommercial-NoDerivatives (CC BY-NC-ND)

Metrics

Views and Downloads

About views and downloads

If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP